相达生物获3400万美元融资，开发宫颈癌早筛新方式，HPV尿液检测离应用还有多远

Group 1 - Several diagnostic companies are developing HPV testing products, but no HPV urine test or home testing product has been approved in China [1] - Xiangda Biotechnology announced the completion of a $34 million Series A financing, marking the largest Series A financing in the Asian diagnostic technology sector since 2019 [1] - The company has developed the world's first HPV urine genetic testing, providing new possibilities for early screening of diseases like cervical cancer [1] Group 2 - Teal Health received FDA approval for the first home cervical cancer screening test, which allows for remote medical consultations and self-sampling at home [1] - The self-sampling method used by Teal Health is invasive, while urine testing is non-invasive, which is preferred by 80% of people according to surveys [2] - Xiangda's urine test has shown a sensitivity of 93.4% for CIN2+ lesions and over 97% consistency with the gold standard test [2] Group 3 - The cost of Xiangda's urine test is currently comparable to the gold standard testing method, with plans to reduce costs to match domestic vaginal swab testing within a year [3] - There is a significant gap in early cervical cancer screening for women, with targets set by the National Health Commission to reach a screening rate of 50% by 2025 and 70% by 2030 [3] - The introduction of urine testing products could meet the unmet demand in the cervical cancer early screening market and open up the male HPV testing market [3]